Is It Too Late To Reassess ImmunityBio (IBRX) After Its 315% Year To Date Surge [Yahoo! Finance]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Yahoo! Finance
If you are wondering whether ImmunityBio's current share price still makes sense after a big run, looking closely at what the market is paying for the business can be just as important as following the headlines. The stock closed at US$8.39 most recently, with returns of 28.3% over 30 days, 315.3% year to date and 192.3% over the past year. The 3 year return is very large and the 5 year return shows a 76.4% decline, which hints at shifting expectations and changing risk appetite over different timeframes. Recent coverage has focused on ImmunityBio's progress and position within the pharmaceuticals and biotech space, helping shape views on its future prospects and funding needs. This context around its pipeline, regulatory milestones and capital structure helps explain why the share price has seen such sharp moves in both directions. On our framework of six valuation checks, ImmunityBio scores 2 out of 6, which you can see in more detail in its valuation score . Next we will wal
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio (IBRX) Climbs 7.3% as Firm Nears Development of ‘World Bank of NK Cells' [Yahoo! Finance]Yahoo! Finance
- IBRX Stock: Anktiva's Approvals and What Comes Next [Yahoo! Finance]Yahoo! Finance
- ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors [Yahoo! Finance]Yahoo! Finance
- ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer DonorsBusiness Wire
- ImmunityBio (IBRX) had its "buy" rating reaffirmed by BTIG Research. They now have a $13.00 price target on the stock.MarketBeat
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 2/26/26 - Form 4
- 2/25/26 - Form SCHEDULE
- 2/24/26 - Form 4
- IBRX's page on the SEC website